New article, titled
Ozempic and Mounjaro are More Than Just Weight Loss Drugs: GLP-1 and GIP Agonists as Partitioning Agents:
https://thinksteroids.com/articles/...t-loss-glp1-gip-agonists-partitioning-agents/
I
do not intend to make the case that incretins are as potent as Clen (clenbuterol HCl) which is,
per-mg, more potent than testosterone in its anabolic effects (and enhancement of muscle power & strength and sprint perofrmance) albeit subject to a rapid diminution in this effect with time (due to β₂AR tachyphylaxis or desensitization), and subject to a threshold or ceiling at which side effects outweight benefits.
I
do not intend to make the case that incretin drugs can overcome severe energy deficits (i.e., kcal restriction) & protein deficiency to enhance recomp or cutting! For those familiar with Patrick Arnold's latest blog post, this is the third or tertiary factor at play in his data, insufficient energy & protein ingestion.
Sections:
1. Recomp vs. Partitioning, and the concept of the
p-ratio explained, including explanations of
insulin resistance vs. sensitivity and the importance of
leptin and hormones
2. Incretins: GLP-1 & GIP agonists, and how they serve to
enhance insulin sensitivity
4. Lipolytic agents: why drugs like clen & stimulants like ephedrine work for fat loss although they cause
insulin resistance
5. Evidence that incretins
enhance body composition by
maintaining FFMI & skeletal muscle index & preferentially reduce fat stores, even in instances devoid of resistance training and controlled nutritional adherence to high protein ingestion & modest deficits (that you
must practice for any substantial recomp effect)
6. Distinction between insulin resistance & hyperglycemia (common bodybuilding misunderstandings of IR)
7. How exogenous insulin (slin)
worsens insulin sensitivity despite ameliorating hyperglycemia.
@qbkilla I had mentioned that I'd share this article with you when it became available
@cmryan For pertinent data